Categories Uncategorized

MustGrow Biologics Corp. (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0) Disrupting Global Agricultural Markets

  • Company shares update of biopesticide product pipeline
  • MGROF committed to combating deadly crop diseases, pests in Colombia and North America
  • MustGrow touts potential additional uses as bioherbicide, sprout suppressor

MustGrow Biologics (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0), an agriculture biotech company focused on providing natural science-based biological solutions for high-value crops and other markets, recently provided an update of its biopesticide product pipeline (https://ibn.fm/eOTGT). By extracting natural compounds from within the mustard seed — the mustard plant’s natural defense mechanism — the company has provided natural solutions to potentially replace widely used harmful synthetics that are being banned and deregistered.

As part of the update, the company reported that a U.S. EPA registration already exists for its biopesticide product in granule format for use as a preplant soil treatment for high-value crops such as fruits and vegetables. The company is now working to obtain a new registration for its biopesticide in liquid format. As with the granular biopesticide, the liquid format is also made from food-grade mustard and has the same active ingredient: AITC. The new liquid biopesticide will be called TerraMG, and MustGrow is anticipating EPA approvals this year.

TerraMG has proved effective in the control of clubroot, a disease destroying Canada’s canola crop, in laboratory and greenhouse. Clubroot spores travel easily, and currently no effective solution exists to control the disease in infected fields. Farmers have had to take extreme precautionary measures to protect against the disease; those measures include crop rotation and seeking resistant varieties of canola. Once a field is infected with clubroot, it can lead to 100% crop loss. With initial efficacy trials completed in both laboratory and greenhouse facilities, MustGrow is working to replicate the same results in field studies (https://ibn.fm/63aqj).

Canada isn’t the only country set to benefit from MustGrow’s biopesticide technology. In 2019 Colombia declared a national state of emergency due to Fusarium wilt TR4, also referred to as the Panama disease. This devastating pathogen has ravaged the $25 billion global banana industry. MustGrow has accomplished something the company believes no other agriscience team has yet to achieve: 100% control of Fusarium wilt TR4 in laboratory. Further testing will determine if the patented biopesticide technology will control the disease in field settings (https://ibn.fm/KhB2B).

As the world shifts to safer more sustainable products, synthetic herbicides face high-profile legal and regulatory challenges. The need for bioherbicides is increasing. MustGrow is using its natural mustard-derived biological approach to address this need. In the laboratory, after only 72 hours, herbicidal control was achieved using MustGrow’s products. This success led to the filing of patents for MustGrow bioherbicides. Moving forward, the company will continue to focus testing on hard to kill and herbicide-resistant weeds (https://ibn.fm/sAtJ2).

In addition to in-field application as a biopesticide and bioherbicide of MustGrow’s mustard-derived technology, MustGrow is also looking at post-harvest application for food preservation and disease and pest control. On Oct. 8, 2020, chlorpropham (“CIPC”), the leading agrochemical product for sprout suppression, was banned by the EU. With no effective treatment alternatives, potato storage sites have a major problem. MustGrow is working to create a solution and has announced an exclusive patent licensing from the University of Idaho (https://ibn.fm/Rj0bv). The mustard-derived biopesticides the company uses rely on a natural sprout inhibitor that does not contain synthetic chemicals associated with negative human health consequences.

The global biopesticide market continues to grow as the world makes the shift to ban or deregister synthetic chemicals. According to Markets and Markets, the industry is expected to double, reaching $8.5 billion by 2025. MustGrow’s safe and effective signature products hold the potential to disrupt global agriculture markets traditionally dominated by synthetic chemicals.

For more information, visit the company’s website at www.MustGrow.ca.

NOTE TO INVESTORS: The latest news and updates relating to MGROF are available in the company’s newsroom at https://ibn.fm/MGROF

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Chris@BMW

Share
Published by
Chris@BMW

Recent Posts

The Global Market for Brain Tumor Treatments Will Reach $7.15 Billion by 2035

The global market for brain tumor treatments is experiencing significant transformation powered by advances in…

1 day ago

New Blood Test Shows Potential in Revolutionizing Early Parkinson’s Detection

A team of researchers has developed a “cost-effective” and simple blood test with the potential…

3 days ago

Nutriband Inc. (NASDAQ: NTRB) Is ‘One to Watch’

Nutriband’s AVERSA technology has the potential to improve the safety profile of transdermal drugs susceptible…

3 days ago

Nutriband Inc. (NASDAQ: NTRB) Leading the Way in Transformative Partnerships Formed in Growing Pharma Sector

Strategic partnerships embrace opportunities to foster innovation, streamline processes and ultimately improve the lives of…

4 days ago

Adageis Helps Medical Providers Track and Build Revenue Through Efficient Application of Value-Based Care

Adageis provides clinics and medical groups with AI-powered tools to track financial outcomes tied to…

1 week ago

Blocking an Enzyme in Melanoma Patients Could Overcome Resistance to Immunotherapy

Approximately 65% of patients diagnosed with melanoma are unresponsive to immunotherapy. New research suggests that…

1 week ago